These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36867734)

  • 1. SEPT9 Expression in Hepatic Nodules: An Immunohistochemical Study of Hepatocellular Neoplasm and Metastasis.
    Kmeid M; Park YN; Chung T; Pacheco RR; Arslan ME; Lee H
    Appl Immunohistochem Mol Morphol; 2023 May-Jun 01; 31(5):278-287. PubMed ID: 36867734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant expression of SATB2, CDX2, CDH17 and CK20 in hepatocellular carcinoma: a pathological, clinical and outcome study.
    Kmeid M; Lukose G; Hodge K; Cho D; Kim KA; Lee H
    Histopathology; 2021 Nov; 79(5):768-778. PubMed ID: 34036629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma.
    Oussalah A; Rischer S; Bensenane M; Conroy G; Filhine-Tresarrieu P; Debard R; Forest-Tramoy D; Josse T; Reinicke D; Garcia M; Luc A; Baumann C; Ayav A; Laurent V; Hollenbach M; Ripoll C; Guéant-Rodriguez RM; Namour F; Zipprich A; Fleischhacker M; Bronowicki JP; Guéant JL
    EBioMedicine; 2018 Apr; 30():138-147. PubMed ID: 29627389
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Li B; Huang H; Huang R; Zhang W; Zhou G; Wu Z; Lv C; Han X; Jiang L; Li Y; Li B; Zhang Z
    Dis Markers; 2020; 2020():6289063. PubMed ID: 33178361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Plasma methylated SEPT9 for Predicting Microvascular Invasion and Tumor Proliferation in Hepatocellular Carcinoma.
    Huang F; Yang G; Jiang H; Chen X; Yang Y; Yu Q; Pan B; Wang B; Guo W; Yang W; Zhang C
    Technol Cancer Res Treat; 2022; 21():15330338221144510. PubMed ID: 36573042
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of methylated septin 9 as an adjunct diagnostic and prognostic biomarker in hepatocellular carcinoma.
    Bannaga AS; Alvarez R; Zhou L; Petchey M; Noufaily A; Hitchins MP; Arasaradnam RP
    HPB (Oxford); 2021 Oct; 23(10):1595-1606. PubMed ID: 33931320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative comparison of alpha-fetoprotein and albumin mRNA levels in hepatocellular carcinoma/adenoma, non-tumor liver and blood: implications in cancer detection and monitoring.
    Wong IH; Lau WY; Leung T; Johnson PJ
    Cancer Lett; 2000 Aug; 156(2):141-9. PubMed ID: 10880763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of downregulation of liver fatty acid-binding protein in hepatocellular carcinoma.
    Inoue M; Takahashi Y; Fujii T; Kitagawa M; Fukusato T
    World J Gastroenterol; 2014 Dec; 20(46):17541-51. PubMed ID: 25516669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSMA Immunohistochemistry in Hepatic Neoplasms: A Promising Diagnostic Marker With Potential Theranostic Applications.
    Kmeid M; Park YN; Chung T; Lukose G; Sullivan L; Brar R; Lee H
    Am J Surg Pathol; 2022 Dec; 46(12):1688-1699. PubMed ID: 36190927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of HCC in high-risk population.
    Zheng K; Dai L; Zhao Y; Li L; Li W; Zhang X; Su Q; Wu R; Jiang Y; Chen Y; Ran J
    BMC Gastroenterol; 2023 Jul; 23(1):260. PubMed ID: 37525116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemistry in the Diagnosis of Hepatocellular Carcinoma.
    Choi WT; Kakar S
    Gastroenterol Clin North Am; 2017 Jun; 46(2):311-325. PubMed ID: 28506367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
    Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
    Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma.
    Saeki I; Suehiro Y; Yamauchi Y; Hoshida T; Tanabe N; Oono T; Kawamoto D; Nishimura T; Matsumoto T; Ishikawa T; Shimokawa M; Tamori A; Kawada N; Tamai Y; Iwasa M; Nakagawa H; Nagano H; Takami T; Yamasaki T
    Hepatol Int; 2023 Oct; 17(5):1289-1299. PubMed ID: 37186217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
    Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
    Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
    DU JL; Wei LX; Wang YL
    Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
    Feng H; Li B; Li Z; Wei Q; Ren L
    BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19.
    Tsuji M; Kashihara T; Terada N; Mori H
    Pathol Int; 1999 Apr; 49(4):310-7. PubMed ID: 10365850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
    Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate tumor overexpressed 1 is a novel prognostic marker for hepatocellular carcinoma progression and overall patient survival.
    Chen SP; Zhang LS; Fu BS; Zeng XC; Yi HM; Jiang N
    Medicine (Baltimore); 2015 Jan; 94(4):e423. PubMed ID: 25634174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of β-catenin protein in hepatocellular carcinoma and its relationship with alpha-fetoprotein.
    Ren YJ; Huang T; Yu HL; Zhang L; He QJ; Xiong ZF; Peng H
    J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):846-851. PubMed ID: 27924522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.